Recombinant Human CD89 protein (rFc Tag) (HPLC verified)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human CD89 protein (rFc Tag) (HPLC verified) (Eg1734)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg1734

---

Validation Data Gallery

• 

  Purity of Recombinant Human CD89 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

---

Product Information

• Purity: >90 %, SDS-PAGE; >90 %, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CD89 protein Gln22-Asn227 (Accession# P24071-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 2204
• Accession: P24071-1
• PredictedSize: 49.8 kDa
• SDS-PAGE: 55-85 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

FcαRI (CD89) is a member of the Fc receptor immunoglobulin superfamily, constitutively expressed on cells of the myeloid lineage like neutrophils, eosinophils, monocytes macrophages, and platelets. CD89 expression and activation are increased in human blood phagocytes following bacterial infection, together with increased expression and association of FcRγ with CD89. CD89 binds both subclasses of IgA (IgA1 and IgA2) with moderate affinity, but also binds other molecules such as TfR1, C-reactive protein and bacterial ligands. CD89 represents an effective target molecule for immunotherapy mediated by bispecific antibodies.

References:

1. Cambier A, et al. (2022). Kidney Int. Feb;101(2):274-287.
2. de Tymowski C, et al. (2019). Cell Rep. Apr 16;;27(3):762-775.e5.
3. Lua WH, et al. (2017). Cell Cycle. Mar 4;16(5):457-467. 
4. van Delft MAM, et al. (2023). Front Immunol. Apr 4;14:1118539.